 The primary objective of this study is to determine the maximum tolerated dose MTD of lovastatin and docetaxel in patients with various different cancers phase I. Once the MTD for this drug combination has been determined, patients with breast cancer will be entered into a single cohort, the phase II portion of this study, and treated with the MTD doses of both lovastatin and docetaxel. 